<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2025000200004</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x2025000200004</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Evolução da Diabetes Mellitus em ambulatório na Região Centro de Portugal entre 2019 e 2023]]></article-title>
<article-title xml:lang="en"><![CDATA[Evolution of Diabetes Mellitus in an Outpatient Clinic in the Central Region of Portugal between 2019 and 2023]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[Catarina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Abrantes]]></surname>
<given-names><![CDATA[Catarina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Neves]]></surname>
<given-names><![CDATA[Ângela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Correia]]></surname>
<given-names><![CDATA[Carla]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carqueija]]></surname>
<given-names><![CDATA[Cláudia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[Angelina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Presidente da Comissão de Farmácia e Terapêutica da Administração Regional de Saúdedo Centro, I.P.  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Comissão de Farmácia e Terapêutica da Administração Regional de Saúde do Centro, I.P.  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Comissão de Farmácia e Terapêutica da Administração Regional de Saúde do Centro, I.P.  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Comissão de Farmácia e Terapêutica da Administração Regional de Saúde do Centro, I.P.  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Comissão de Farmácia e Terapêutica da Administração Regional de Saúde do Centro, I.P.  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Comissão de Farmácia e Terapêutica da Administração Regional de Saúde do Centro, I.P.  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Brasil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2025</year>
</pub-date>
<volume>35</volume>
<numero>2</numero>
<fpage>115</fpage>
<lpage>128</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2025000200004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2025000200004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2025000200004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo A Diabetes Mellitus é uma doença crónica complexa que requer cuidados médicos contínuos em parceria com o indivíduo, envolvendo medidas farmacológicas e não farmacológicas em simultâneo, para evitar as consequên-cias da hiperglicemia e o aparecimento de outras complicações inerentes, a melhoria da qualidade de vida e o prolongamento de sobrevida do doente. O trabalho desenvolvido consistiu na análise retrospetiva dos encargos com a faturação dos medicamentos utilizados no tratamento da Diabetes Mellitus, tendo em conta o número de embalagens dispensadas, custos totais associados e custos inerentes à comparticipação, na área de influência da Administração Regional de Saúde do Centro (ARS Centro), num período de 5 anos, 2019 a 2023, de modo a perceber a realidade atual e a evolução da doença e da terapêutica associada e, retirar ilações relativas a procedimentos e/ou medidas a adotar para melhoria dos resultados em saúde. Os resultados obtidos mostram que a metformina é o fármaco com maior número de embalagens dispensadas entre 2019 e 2023, de acordo com as recomendações clínicas em vigor, com menores custos associados. O aumento exponencial dos inibidores do cotransportador tipo 2 de sódio-glicose (SGLT2), associados ou não à metformina, e dos análogos do peptídeo similar ao glucagon-1 (GLP-1), em relação à dispensa e custos totais, decorrem da evidência dos seus benefícios cardiovasculares e renais. A análise periódica deste tipo de dados é crucial para encontrar estratégias e ferramentas que enfatizem a implementação de mudanças nos padrões de prescrição e na relação custo/efetividade, bem como a envolvência do doente na sua equipa de saúde.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Diabetes Mellitus is a complex chronic disease that requires continuous medical care in partnership with patient, involving pharmacological and non-pharmacological approach, to avoid the consequences of hyperglycemia and the appearance of other complications, to improving quality of life and to prolonging patient survival. The work developed consisted of a retrospective analysis of charges for charging medications used in the treat-ment of Diabetes Mellitus, considering the number of packages dispensed, total associated costs and costs inherent to copayment, in the area of influence of the Regional Health Administration of the Center, over a period of 5 years between 2019 to 2023, in order to understand the current reality and the evolution of the disease and associated therapy and draw lessons regarding procedures and/or measures to be adopted to improve health outcomes. The results obtained show that metformin is the hypoglycemic agent with the highest number of packages dispensed between 2019 and 2023, in accordance with current clinical recommendations, with lower associated costs. The exponential increase in sodium-glucose cotransporter 2 (SGLT2) inhibitors, whether or not associated with metformin, and glucagon-like peptide-1 (GLP-1) analogues, in relation to dispensing and total costs, results from the evidence of their cardiovascular and renal benefits. Periodic analysis of this type of data is crucial to find strategies and tools that emphasize implementing changes in prescribing patterns and cost-effectiveness, as well as patient involvement in their healthcare team.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Diabetes Mellitus]]></kwd>
<kwd lng="pt"><![CDATA[Cuidados de Saúde Primários]]></kwd>
<kwd lng="pt"><![CDATA[Fármacos Antidiabéticos]]></kwd>
<kwd lng="pt"><![CDATA[Utilização de Medicamentos]]></kwd>
<kwd lng="en"><![CDATA[Diabetes Mellitus]]></kwd>
<kwd lng="en"><![CDATA[Primary Health Care]]></kwd>
<kwd lng="en"><![CDATA[Hypoglycemic Agents]]></kwd>
<kwd lng="en"><![CDATA[Drug Utilization]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>Sociedade Portuguesa de Diabetologia</collab>
<article-title xml:lang=""><![CDATA[Relatório Anual do Observatório Nacional da Diabetes 03/2023]]></article-title>
<source><![CDATA[Diabetes: Factos e Números &#8211; Ano de 2019, 2020 e 2021]]></source>
<year>2003</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>IDF Diabetes Atlas</collab>
<source><![CDATA[Diabetes around the world in 2021]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>National Institute of Diabetes and Digestive and Kidney Diseases</collab>
<source><![CDATA[What&#8217;s New in the 2024 ADA Standards of Care?]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dahlén]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Dashi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Maslov]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Attwood]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Jonsson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Trukhan]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales]]></article-title>
<source><![CDATA[Front. Pharmacol]]></source>
<year></year>
<volume>12</volume>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moura]]></surname>
<given-names><![CDATA[A.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[S.O.]]></given-names>
</name>
<name>
<surname><![CDATA[Raposo]]></surname>
<given-names><![CDATA[J.F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consumption of antidiabetic medicines in Portugal: results of a temporal data analysis of a thirteen-year study (2005- 2017)]]></article-title>
<source><![CDATA[BMC Endocr Disord]]></source>
<year>2021</year>
<volume>21</volume>
<numero>30</numero>
<issue>30</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<collab>Comissão Nacional de Farmácia e Terapêutica</collab>
<source><![CDATA[Recomendações para a Terapêutica Farmacológica da Hiperglicemia na Diabetes Mellitus tipo 2]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association Professional Practice Committee</collab>
<article-title xml:lang=""><![CDATA[Summary of Revisions: Standards of Care in Diabetes&#8212;2024]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2024</year>
<volume>47</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<collab>WHO Collaborating Centre for Drug Statistics Methodology</collab>
<source><![CDATA[ATC/DDD Index]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Monteiro-Soares]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Guerreiro]]></surname>
<given-names><![CDATA[J.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Teixeira-Rodrigues]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimating Type 2 Diabetes Prevalence: A Model of Drug Consumption Data]]></article-title>
<source><![CDATA[Pharmacy]]></source>
<year>2024</year>
<volume>12</volume>
<numero>18</numero>
<issue>18</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carmona Araújo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandes]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Franco Ruivo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[M do C]]></given-names>
</name>
<name>
<surname><![CDATA[Faria Vaz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Furtado]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of Outpatient Use of Medicines by the Elderly Population in Portugal: A Cross-Sectional Study]]></article-title>
<source><![CDATA[Acta Med Port]]></source>
<year>2023</year>
<volume>36</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>792-801</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<collab>INFARMED</collab>
<source><![CDATA[Monitorização do consumo de Medicamentos]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Csatordai]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Benk&#337;]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Matuz]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trends and regional differences in antidiabetic medication use: a nationwide retrospective observational study]]></article-title>
<source><![CDATA[Diabetol Metab Syndr]]></source>
<year>2024</year>
<volume>16</volume>
<numero>88</numero>
<issue>88</issue>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Toyama]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hirakawa]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Jun]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cass]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2018</year>
<volume>9</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment]]></article-title>
<source><![CDATA[Molecules]]></source>
<year>2022</year>
<volume>27</volume>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martin]]></surname>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Takagi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety, efficacy, and cost-effectiveness of insulin degludec U100 versus insulin glargine U300 in adults with type 1 diabetes: a systematic review and indirect treatment comparison]]></article-title>
<source><![CDATA[Int J Clin Pharm]]></source>
<year>2022</year>
<volume>44</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>587-98</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martin]]></surname>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Takagi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety among second-generation and other basal insulins in adult patients with type 1 diabetes: a systematic review and network meta-analysis]]></article-title>
<source><![CDATA[Naunyn Schmiedebergs Arch Pharmacol]]></source>
<year>2021</year>
<volume>394</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2091-101</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Bae]]></surname>
<given-names><![CDATA[J.H.]]></given-names>
</name>
<name>
<surname><![CDATA[Kwon]]></surname>
<given-names><![CDATA[HS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 and diabetes mellitus: from pathophysiology to clinical management]]></article-title>
<source><![CDATA[Nat Rev Endocrinol]]></source>
<year>2021</year>
<volume>17</volume>
<page-range>11-30</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
